Bücher der Reihe Recent Results in Cancer Research

This volume contains the main proceedings of the fourth international conference on "Cancer Prevention 2006," which was held during February 16-18, 2006, in St. Gallen, Switzerland.

The meeting was generously supported again by the Federal Ministry of Research and Technology (Bundesministe rium flir Forschung und Technologie, BMFT) within the framework of the West German BMFT Breast Cancer Study Group.

Detailed attention is also paid to other important recent developments, including molecular response prediction, early metabolic response evaluation by PET and PET-CT, the diagnosis of micrometastases, and the use of sentinel node technology.

The principal focus, however, is on therapy, with detailed information on the various promising treatment options which give hope that this cancer will be transformed into a chronic disease or even become curable.

Offering detailed explanations, it discusses the how changes in tumors can be tracked using these cutting-edge technologies, which enable the detection and analysis of diverse circulating biomarkers: tumor cells, tumor DNA, tumor RNA (free or in exosomes), and fluid biomarkers identifiable by means of targeted proteomics.

This book is based on contributions presented at the 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy, which examined recent developments in theranostics - the emerging field of molecular targeting of vectors that can be used for both diagnosis and therapy, when modified accordingly.

This book reviews current research in peritoneal malignant dissemination, from its pathogenesis and molecular mechanisms to the latest clinical trials. The book covers the essentials of perioperative intraperitoneal chemotherapy and modern histopathological assessment of peritoneal surface malignancy.

This volume contains the main proceedings of the fourth international conference on "Cancer Prevention 2006," which was held during February 16-18, 2006, in St. Gallen, Switzerland.

More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention.

Modern imaging methods have made it possible to detect breast cancer at an earlier stage than in the past. Further chapters are devoted to the pathology of the breast tissue obtained using these procedures, their limitations, the implications of recent advances in breast imaging, and the results of cost-benefit analyses.

Furthermore, mucosal inflammation, even if subtle, is the single most common pathway for GI cancer. This book discusses all aspects of the relation between inflammation and GI cancer, from the basic science through to the translational science which is helping in the optimization of clinical management strategies.

This book is based on presentations by some of the world's leading experts at the Sixth International Conference on Clinical Cancer Prevention, held in St. Gallen, Switzerland, during March 2010.

Gliomas, which comprise astrocytic, oligodendroglial, and ependymal lesions, are the most frequent primary intracranial tumors. The first part of the book focuses on the glial tumor entities, with detailed discussion of diagnosis, molecular genetics, and tumor origin.

This book does nothing less than lay out the state of development of tomorrow's cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities.

This book examines in detail the psychosocial impacts of cancer and its management, explaining the relevance of psycho-oncology during all stages from diagnosis and treatment through to cancer survivorship and rehabilitation and end-of-life care.

The development of optimal sun screens and UV-protective clothes, new tools for early diagnosis of malignant lesions including videomicroscopy, improved evaluation of biopsy material and new treatment schemes will contribute to better patient care.

It is now widely accepted that multidisciplinary collaboration and multimodality treatment approaches are important in improving the survival of patients with hepatocellular carcinoma.

Acquired immunodeficiencies are caused by infections with the human immunodeficiency virus or arise following immunosuppressive therapy administered after organ transplantation or to treat connective tissue diseases such as rheumatoid arthritis.

It is now widely accepted that multidisciplinary collaboration and multimodality treatment approaches are important in improving the survival of patients with hepatocellular carcinoma.

The development of optimal sun screens and UV-protective clothes, new tools for early diagnosis of malignant lesions including videomicroscopy, improved evaluation of biopsy material and new treatment schemes will contribute to better patient care.

Cellular transformation and carcinogenesis are considered a multistep process starting with DNA lesions and progressing through loss of cellular growth control and increase invasive and metastatic properties.

While amputation used to be the surgical treatment of choice limb-saving procedures have now become an im portant therapeutic modality in treating such lesions, particularly in combination with percutaneous or interstitial radiotherapy.

We often hear physicians, health care professionals, poli ticians, and patient advocates that "nothing has happened in the treatment of breast cancer," since patients with breast cancer, the most frequent neoplastic condition in women in industrialized countries, are continuing to suffer relapse and succumb to this dreadful disease!

Almost a century ago Paul Ehrlich introduced the "magic bullet" concept of targeting therapeutic agents to specific tissues in order to reduce systemic toxicity.

From the 1960s onward, the pioneer work of a few investigators clearly showed that hereditary factors were not only related to rare neoplasms, but could also be respon sible for the occurrence of a sizeable fraction of tumors that do not usually show features of inheritance (as in the case of breast or colorectal cancer).

In spite of great advance made by ENT and maxillofacial surgeons as well as radiotherapists to improve therapy of cancer of the oral cavity and oropharynx, it has not been possible in the past 4 decades to raise the chances of patient survival above 40%-45%.